MICAL1

Across TCGA pan-cancer cohorts, MICAL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MICAL1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MICAL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MICAL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

GBM, LSCC, and LUAD are the cancer types where MICAL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.390	0.743	<.001	17	view →
LSCC	OS	Quartile	II,III,IV	0.612	1.000	.007	10	view →
LUAD	OS	Tertile	III,IV	0.294	0.790	.017	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
PDAC	OS	Tertile	All	0.538	0.314	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MICAL1–GBM (OS)

Open the GBM breakdown →